Humira vs Enbrel vs Rinvoq Cost 2026

Quick Answer: In 2026, Humira costs $550 to $6,922 per month depending on whether you use an unbranded biosimilar or the brand, Enbrel costs $2,355 per month for Medicare Part D enrollees under its IRA-negotiated Maximum Fair Price (versus $6,800 to $7,500 cash price without insurance), and Rinvoq costs $6,245 to $9,104 per month with no generic or biosimilar available until an expected 2037 patent settlement date. Only Enbrel was selected for Round 1 Inflation Reduction Act negotiation; Humira and Rinvoq are not IRA-negotiated. AbbVie's myAbbVie Assist program covers both Humira and Rinvoq for uninsured patients at or below 600% of the Federal Poverty Level, though Humira is being phased out of that program for new applicants starting July 1, 2026 because biosimilars now exist. Amgen's Safety Net Foundation offers free Enbrel to uninsured patients meeting separate income criteria. Because Rinvoq carries an FDA boxed warning restricting its use to patients who already tried and failed a TNF inhibitor like Humira or Enbrel, most insurers require documented step therapy before covering it, which shapes both the clinical and cost pathway for new RA patients.

Humira (adalimumab), Enbrel (etanercept), and Rinvoq (upadacitinib) are three of the most-prescribed disease-modifying antirheumatic drugs (DMARDs) for moderate to severe rheumatoid arthritis in the United States, and their 2026 costs diverge sharply for three separate reasons: biosimilar competition, Inflation Reduction Act negotiation status, and small-molecule patent protection. Humira and Enbrel are both large-molecule biologic TNF (tumor necrosis factor) inhibitors given by subcutaneous injection, while Rinvoq is a small-molecule oral JAK (Janus kinase) inhibitor taken as a once-daily tablet. That mechanism difference drives an important prescribing rule: the FDA requires most JAK inhibitors, including Rinvoq, to carry a boxed warning limiting their use to patients who have already tried and failed, or cannot tolerate, a TNF inhibitor like Humira or Enbrel. For single-drug detail beyond this comparison, see the dedicated pages for Humira cost, Enbrel cost, and Rinvoq cost.

The Inflation Reduction Act of 2022, signed August 16, 2022, authorized CMS to negotiate Medicare drug prices directly with manufacturers for the first time. Enbrel was one of the first 10 drugs selected for Round 1 negotiation, and its Maximum Fair Price of $2,355 per 30-day supply took effect January 1, 2026, a 67% cut from its $7,106 list price. Humira and Rinvoq were not selected for Round 1: Humira because biosimilar competitors already existed by the statutory selection date, and Rinvoq because CMS's initial 10-drug list focused on the highest Medicare Part D spend at the time of selection in 2023, before Rinvoq's spending had grown large enough to qualify. Neither exclusion means Humira or Rinvoq is cheap; it means their 2026 cost depends entirely on biosimilar competition (Humira) or manufacturer patient assistance and formulary placement (Rinvoq) rather than a federally negotiated price.

Rheumatologists typically start newly diagnosed RA patients on methotrexate, a low-cost conventional DMARD running $10 to $30 per month generic, before escalating to a biologic or JAK inhibitor if disease activity remains high. Patients who need to escalate usually try Humira or Enbrel first, both because those two TNF inhibitors have decades of safety data and because most insurance formularies require documented TNF inhibitor failure before approving Rinvoq under the FDA's step-therapy-aligned labeling. Switching between these three drugs for cost reasons requires prescriber input, since Humira and Enbrel have different injection schedules (biweekly versus weekly) and Rinvoq carries its own cardiovascular and blood clot warnings that some patients cannot safely take regardless of price. The comparison table below lays out cash price, Medicare Part D treatment, biosimilar or generic status, and manufacturer patient assistance program for all three drugs side by side.

What RA Medication Cost Comparison Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same ra medication cost comparison can cost many times more at a hospital than at your local pharmacy:

2026 RA Medication Cost Comparison Price by Point of Pay
Where you pay	Typical cost	Notes
Pharmacy counter (retail, brand-name cash price)	$6,245 - $9,104/month	Brand Humira runs $6,380 - $6,922; brand Enbrel runs $6,800 - $7,500; brand Rinvoq runs $6,245 - $9,104 in 2026; see comparison table above for per-drug detail
Biosimilar or GoodRx discount coupon	$550 - $7,836/month	Unbranded adalimumab-adaz (Humira biosimilar) runs about $550/month; Enbrel's lowest GoodRx coupon price runs about $3,354/month; Rinvoq has no biosimilar, so its best 2026 discount price is about $6,245/month
Medicare Part D (2026, IRA Maximum Fair Price where applicable)	$2,355/month for Enbrel, or formulary tier copay for Humira/Rinvoq	Enbrel's $2,355 Maximum Fair Price applies at any network pharmacy through 2026; Humira and Rinvoq costs depend on your plan's formulary tier for brand versus biosimilar (Humira) or on prior authorization approval (Rinvoq)
Commercial insurance with manufacturer savings card	$0 - $5/month copay	HUMIRA Complete, the Enbrel Co-Pay Program, and RINVOQ Complete each cap commercially-insured copays around $0 to $5 per month up to an annual maximum benefit; none of the three cards can be used with Medicare, Medicaid, TRICARE, or VA
Medicaid	$1 - $4/prescription	Most state Medicaid formularies prefer a specific TNF inhibitor or require step therapy through methotrexate before covering any of the three drugs; check your state Medicaid income limits for household eligibility rules

Medicare IRA Maximum Fair Price for Enbrel effective January 1, 2026 per CMS. Retail and biosimilar prices from GoodRx 2026 data. Medicaid cost-sharing varies by state; check your state's Medicaid income limits page for household eligibility rules.

Source: CMS IRA Negotiated Prices 2026, CMS Medicare Part D 2026 Benefit Parameters, GoodRx, manufacturer savings programs

Why Hospitals Charge So Much

Specialty pharmacies, not hospital pharmacies, dispense Humira, Enbrel, and Rinvoq in the vast majority of cases, because all three require cold-chain shipping (Humira and Enbrel) or specific handling protocols and prior authorization paperwork (all three) that standard retail pharmacy counters are not set up to process. When any of the three is instead administered or dispensed during an inpatient hospital stay, for example after a severe RA flare with another complicating diagnosis, Medicare bundles the cost into the Diagnosis-Related Group (DRG) payment for that admission rather than billing it as a separate line item, and commercial insurers negotiate their own bundled inpatient rates separately from any retail price.

Rinvoq's inpatient facility rate runs highest of the three, up to $27,000 for a month-equivalent supply, because hospital pharmacies that do stock a small-molecule oral RA drug for an admitted patient typically mark up the per-tablet chargemaster rate well above the outpatient specialty pharmacy price, and few hospital formularies stock it in volume given how rarely it is used inpatient. Medicare Part A stops paying for any of the three drugs the moment a patient is discharged, and coverage shifts entirely to Part D for the outpatient prescription, which is where Enbrel's 2026 IRA Maximum Fair Price of $2,355 per month kicks in.

Methotrexate, the decades-old generic conventional DMARD, remains the lowest-cost fallback across all three biologic and JAK inhibitor scenarios at roughly $10 to $30 per month, but it works more slowly and less powerfully for moderate to severe RA than any of the three drugs compared here. Patients who cannot afford Humira, Enbrel, or Rinvoq should ask their rheumatologist whether a biosimilar switch, methotrexate combination therapy, or a manufacturer patient assistance program is clinically appropriate rather than skipping doses, since uncontrolled RA can cause permanent joint damage.

HCPCS J-Codes: What Appears on Your Bill

Humira and Enbrel each carry a HCPCS Level II J-code, used when a clinic or infusion suite administers or bills the drug directly rather than a patient self-injecting a take-home prescription billed through Part D. Rinvoq is an oral tablet with no J-code because it is never administered by a clinician.

HCPCS J-codes for RA Medication Cost Comparison
Code	Description	What to look for
J0139	Injection, adalimumab, 1 mg (covers brand Humira and all FDA-approved adalimumab biosimilars; replaced the discontinued 20mg-unit code J0135 effective January 1, 2025)	Confirm the number of 1mg units billed matches your actual dose (standard adult RA dosing is 40mg biweekly, or 40 units, not 2); this single code now applies to brand Humira and every adalimumab biosimilar, so ask the billing office which specific product was dispensed
J1438	Injection, etanercept, 25mg	Standard adult RA dosing is 50mg weekly, or 2 units per week; check that this code was not billed for a dose you actually self-administered at home under Part D

These J-codes appear on Medicare Part B claims only when a provider's office or infusion center administers the dose, which is uncommon for these three RA drugs since nearly all patients self-inject or self-administer at home under Part D. If you see one of these codes on a bill for a dose you gave yourself, ask your provider's billing office to correct the claim.

Source: CMS HCPCS Level II Code Set 2026

Lower your hospital bill. Or get it forgiven.

Free in 30 seconds. We check every charge for errors and overcharges, see if you qualify for free care at your hospital, and write a custom dispute letter ready to send. Most patients save hundreds.

Lower my bill — free

Patient Assistance Programs

AbbVie and Amgen each run separate patient assistance programs for their RA drugs, and a critical 2026 change affects Humira specifically. If you have no insurance and a modest income, your RA medication cost may be $0 through the correct manufacturer program, but you must apply to the manufacturer of your specific prescribed drug; there is no single combined RA assistance program covering all three.

Patient assistance programs for RA Medication Cost Comparison
Manufacturer program	Cost / Benefit	How to apply
myAbbVie Assist - Humira (closing to new applicants July 1, 2026)	Free Humira for uninsured or underinsured patients at or below 600% FPL ($95,760 for a household of 1 in 2026); no new Humira applications accepted after July 1, 2026 because biosimilars now exist, though currently enrolled patients continue through their eligibility term	abbvieaccess.com/patient-assistance
myAbbVie Assist - Rinvoq (remains open)	Free Rinvoq for uninsured patients at or below 600% FPL; some Medicare Part D patients without Extra Help may also qualify	abbvie.com/myabbvieassist
Amgen Safety Net Foundation - Enbrel	Free Enbrel for uninsured or underinsured patients with household income at or below approximately 400% FPL	amgensafetynetfoundation.com
NeedyMeds Drug Discount Card	Variable discount on any of the three RA drugs, accepted at most US pharmacies, no income limit	needymeds.org

Manufacturer savings cards for all three drugs (HUMIRA Complete, the Enbrel Co-Pay Program, and RINVOQ Complete) are not available to Medicare, Medicaid, TRICARE, or VA beneficiaries by federal law, the anti-kickback statute at 42 U.S.C. Section 1320a-7b. If you have any government insurance, use the manufacturer's income-based patient assistance program instead of a savings card, or apply for Medicare Part D Extra Help through Social Security at 1-800-772-1213.

Source: abbvieaccess.com, abbvie.com/myabbvieassist, amgensafetynetfoundation.com, needymeds.org

Medicare Part D

Medicare Part D treats these three RA drugs very differently in 2026. Enbrel is subject to the IRA Maximum Fair Price of $2,355 per month, applied at any network pharmacy regardless of which specific plan you carry. Humira and Rinvoq have no negotiated price; your out-of-pocket cost depends entirely on your Part D plan's formulary tier, and most plans place an interchangeable Humira biosimilar on a lower tier with a smaller copay than brand Humira. All out-of-pocket spending on any of the three drugs counts toward the same 2026 Part D annual out-of-pocket cap of $2,100; once you hit that cap across all your Part D drugs combined, you pay $0 for the rest of the calendar year.

Extra Help, the Part D Low Income Subsidy, reduces cost-sharing further for Medicare beneficiaries with limited income and resources. In 2026, Extra Help enrollees pay $12.65 per fill for a brand-name drug like brand Humira, Enbrel, or Rinvoq, and a smaller copay for an interchangeable Humira biosimilar. Extra Help is generally available to beneficiaries with income at or below 150% of the Federal Poverty Level. Apply through the Social Security Administration at 1-800-772-1213 or at ssa.gov, and mention which specific RA drug you take since eligibility rules for the manufacturer PAP on top of Extra Help vary by drug.

Common RA Medication Cost Comparison Billing Errors

Watch for these RA-specific billing issues across Humira, Enbrel, and Rinvoq claims:

Specialty pharmacy or plan charges more than the $2,355 Enbrel IRA Maximum Fair Price for a Medicare Part D 30-day fill in 2026, which violates federal law; ask your plan's member services to reprocess the claim.
A pharmacy substitutes an interchangeable Humira biosimilar without notifying you, which is legal in most states but should still appear correctly on your bill and formulary tier.
Manufacturer copay card (HUMIRA Complete, the Enbrel Co-Pay Program, or RINVOQ Complete) applied to a patient enrolled in Medicare or Medicaid, which is prohibited and can trigger a claim clawback later.
Rinvoq prior authorization denied without your rheumatologist documenting the FDA-required prior TNF inhibitor trial or intolerance; this is a paperwork fix, not a true coverage denial.
J1438 (Enbrel) or J0139 (Humira or an adalimumab biosimilar) billed under Part B for a dose you actually self-administered at home, which should instead be billed under Part D.
Charged the standard formulary copay after you already reached the 2026 Part D annual out-of-pocket cap of $2,100 across all your combined Part D drugs.

Frequently Asked Questions

Is there a generic or biosimilar for Humira, Enbrel, or Rinvoq?

Yes for two of the three. Humira has more than 10 FDA-approved biosimilars, with 7 holding interchangeable status as of 2026, and the unbranded version costs about $550 per month. Enbrel has two approved biosimilars, Erelzi and Eticovo, but a patent settlement blocks both from the US market until 2029. Rinvoq is a small-molecule drug with no biosimilar pathway; a generic is not expected until around April 2037 following a September 2025 patent settlement.

How do I apply for the Humira, Enbrel, or Rinvoq patient assistance program?

Apply to the manufacturer of your specific drug: myAbbVie Assist at abbvieaccess.com for Humira (new applications close July 1, 2026) or Rinvoq (remains open), or the Amgen Safety Net Foundation at amgensafetynetfoundation.com for Enbrel. Each requires proof of income, US residency, a valid prescription, and documentation of no prescription drug coverage. Processing takes 7 to 15 business days, and approved enrollment typically lasts 12 months with annual re-verification.

Can I use a Humira, Enbrel, or Rinvoq savings card with Medicare?

No. Federal anti-kickback law, 42 U.S.C. Section 1320a-7b, bars Medicare, Medicaid, TRICARE, and VA beneficiaries from using any manufacturer copay savings card, including HUMIRA Complete, the Enbrel Co-Pay Program, and RINVOQ Complete. Medicare Part D patients on Enbrel should instead rely on the 2026 IRA Maximum Fair Price of $2,355, and Humira or Rinvoq patients should apply for Part D Extra Help or the matching manufacturer PAP if they cannot afford the formulary copay.

What if my insurance denies coverage for Humira, Enbrel, or Rinvoq, or requires step therapy?

Request a written denial notice, then file a formal appeal within 60 days with a rheumatologist letter documenting medical necessity. Rinvoq denials often require documenting a prior TNF inhibitor trial or intolerance, matching the FDA's own boxed warning restriction. If your plan requires step therapy, your rheumatologist can file a step-therapy exception documenting inadequate response, adverse events, or contraindication. If the appeal fails, apply for the manufacturer PAP that matches your specific drug.

Does the IRA negotiated price apply to Humira, Enbrel, or Rinvoq?

It applies only to Enbrel. Enbrel was selected for Medicare's first round of Inflation Reduction Act negotiation, with a Maximum Fair Price of $2,355 per month, effective January 1, 2026, a 67% reduction from its $7,106 list price. Humira was excluded because biosimilar competition already existed, and Rinvoq was not part of the initial 10-drug negotiation list. Out-of-pocket spending on all three still counts toward the 2026 Part D annual cap of $2,100.

What does each RA drug cost without insurance at the pharmacy counter in 2026?

Without insurance, brand Humira runs $6,380 to $6,922 per month, brand Enbrel runs $6,800 to $7,500 per month, and brand Rinvoq runs $6,245 to $9,104 per month. With a biosimilar or GoodRx coupon, the unbranded Humira biosimilar drops to about $550 per month, Enbrel drops to about $3,354 per month with the best GoodRx coupon, and Rinvoq, which has no biosimilar, stays at its lowest cash price of about $6,245 per month.

Do I qualify for a patient assistance program based on my income?

It depends on which drug you take. myAbbVie Assist, covering Humira and Rinvoq, generally requires household income at or below 600% of the Federal Poverty Level, or $95,760 for one person in 2026. The Amgen Safety Net Foundation for Enbrel uses a stricter threshold of roughly 400% FPL. Check the specific program for your prescribed drug, and note that Humira's program stops accepting new applicants July 1, 2026.

Which is cheaper: Humira, Enbrel, or Rinvoq, and why does a TNF inhibitor versus JAK inhibitor matter for cost?

For uninsured patients without a PAP, an interchangeable Humira biosimilar is by far the cheapest at about $550 per month, since it is the only one of the three with a mature, competitive biosimilar market. Enbrel is often cheapest for Medicare Part D patients because of its 2026 IRA Maximum Fair Price of $2,355. Rinvoq stays the most expensive of the three because it has no generic or biosimilar competition, and its class-wide FDA boxed warning means most insurers require you to fail a TNF inhibitor like Humira or Enbrel first, which also delays access to it.